Lutz Harnisch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lutz Harnisch has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Sébastien Bihorel
Regeneron Pharmaceuticals, Inc. Tarrytown New York USA
4 shared publications John D. Davis
Regeneron Pharmaceuticals, Inc Tarrytown New York USA
3 shared publicationsA. Thomas DiCioccio
Regeneron Pharmaceuticals, Inc. Tarrytown New York USA
2 shared publicationsJeanne Mendell
Regeneron Pharmaceuticals, Inc. Tarrytown New York USA
2 shared publications- Joannellyn Chiu
Regeneron Pharmaceuticals, Inc Tarrytown New York USA
2 shared publications - John D. Davis
Regeneron Pharmaceuticals, Inc. Tarrytown New York USA
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (11) , e70350
Reply to “Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration”
- 15 October 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (11) , e70350
Open AccessReply to “Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration”
- Open Access
- 30 June 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (7) , e70287
Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products
Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in both diseases. In pivotal trials, a high‐dose drug product (AFL‐HD) using a formulation distinct from AFL‐2 and delivering 8‐mg aflibercept every 12 or 16 weeks (following initial monthly dosing) provided visual gains non‐inferior to AFL‐2 administered every 8 weeks (following initial monthly dosing) and comparable safety with fewer injections over 96 weeks. Free and bound aflibercept concentrations in plasma from 2744 participants in 16 clinical trials where aflibercept was administered intravitreally, subcutaneously, or intravenously were analyzed by population pharmacokinetic modeling. A semi‐mechanistic model described the release of free aflibercept from the eye and its target‐mediated elimination from plasma. The evaluated covariates (weight, age, sex, albumin, disease, racial classification, Japanese origin, renal and hepatic functions) resulted in only small numerical differences in systemic exposure. Ocular clearance ( Q E ; characterizing the bidirectional transfer of free aflibercept between the eye and central compartment) was comparable across both diseases after adjusting for an age‐dependent decrease. The change in drug product, and not just the dose increase, was responsible for a 39.4% slower Q E and extended exposure in the ocular space for AFL‐HD versus AFL‐2. The median ocular concentrations of free aflibercept predicted at the end of the 8‐week dosing interval for AFL‐2 were typically reached 14 weeks after AFL‐HD injections, versus 9–9.5 weeks if Q E was identical for both drug products.
- 30 June 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (7) , e70287
Open AccessIntegrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products
Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in both diseases. In pivotal trials, a high‐dose drug product (AFL‐HD) using a formulation distinct from AFL‐2 and delivering 8‐mg aflibercept every 12 or 16 weeks (following initial monthly dosing) provided visual gains non‐inferior to AFL‐2 administered every 8 weeks (following initial monthly dosing) and comparable safety with fewer injections over 96 weeks. Free and bound aflibercept concentrations in plasma from 2744 participants in 16 clinical trials where aflibercept was administered intravitreally, subcutaneously, or intravenously were analyzed by population pharmacokinetic modeling. A semi‐mechanistic model described the release of free aflibercept from the eye and its target‐mediated elimination from plasma. The evaluated covariates (weight, age, sex, albumin, disease, racial classification, Japanese origin, renal and hepatic functions) resulted in only small numerical differences in systemic exposure. Ocular clearance ( Q E ; characterizing the bidirectional transfer of free aflibercept between the eye and central compartment) was comparable across both diseases after adjusting for an age‐dependent decrease. The change in drug product, and not just the dose increase, was responsible for a 39.4% slower Q E and extended exposure in the ocular space for AFL‐HD versus AFL‐2. The median ocular concentrations of free aflibercept predicted at the end of the 8‐week dosing interval for AFL‐2 were typically reached 14 weeks after AFL‐HD injections, versus 9–9.5 weeks if Q E was identical for both drug products.
- Open Access
- 5 December 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (1)
Pharmacokinetics of Odronextamab, A Bispecific T‐Cell‐Engaging Antibody, in Adult Patients With Relapsed or Refractory B‐Cell Non‐Hodgkin Lymphoma
Non‐Hodgkin lymphoma (NHL) is the fifth most common malignancy and accounts for 5% of all cancers in the US, with the largest proportion being B‐cell CD20 positive NHL. Odronextamab is a CD20xCD3 IgG4 bispecific T‐cell‐engaging monoclonal antibody under development for the treatment of relapsed or refractory (R/R) B‐NHL. The objectives of this analysis were to characterize the pharmacokinetics (PK) of odronextamab in adult patients, and elucidate sources and correlates of variability. PK data of 507 patients with R/R B‐NHL from ELM‐1 (NCT02290951, Phase I; n = 167) and ELM‐2 (NCT03888105, Phase II; n = 340) were analyzed. Odronextamab concentration–time profiles following intravenous administration of 0.03 mg to 320 mg doses were described by a bi‐exponential decline with parallel linear (first‐order) and non‐linear (Michaelis–Menten) elimination processes. The modified Michaelis–Menten or target‐mediated elimination was not only concentration–dependent but also time‐dependent. A reduction in target‐mediated clearance over time suggests a reduction in target abundance to a larger extent than associated with concentration alone, which is consistent with the treatment‐induced depletion of the B cells observed in patients who underwent assessment. Linear clearance (CL) and steady‐state volume of distribution were 0.189 L/day and 9.41 L, respectively. Target‐mediated clearance was ~5 L/day at baseline, with an asymptote of ~0.03 L/day at steady state. With the largest covariate effect on odronextamab exposure, baseline body weight was directly correlated with CL and volume of distribution, albumin was inversely correlated with CL and volume of distribution, and baseline interleukin‐10 was inversely correlated with CL.
- 5 December 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (1)
Open AccessPharmacokinetics of Odronextamab, A Bispecific T‐Cell‐Engaging Antibody, in Adult Patients With Relapsed or Refractory B‐Cell Non‐Hodgkin Lymphoma
Non‐Hodgkin lymphoma (NHL) is the fifth most common malignancy and accounts for 5% of all cancers in the US, with the largest proportion being B‐cell CD20 positive NHL. Odronextamab is a CD20xCD3 IgG4 bispecific T‐cell‐engaging monoclonal antibody under development for the treatment of relapsed or refractory (R/R) B‐NHL. The objectives of this analysis were to characterize the pharmacokinetics (PK) of odronextamab in adult patients, and elucidate sources and correlates of variability. PK data of 507 patients with R/R B‐NHL from ELM‐1 (NCT02290951, Phase I; n = 167) and ELM‐2 (NCT03888105, Phase II; n = 340) were analyzed. Odronextamab concentration–time profiles following intravenous administration of 0.03 mg to 320 mg doses were described by a bi‐exponential decline with parallel linear (first‐order) and non‐linear (Michaelis–Menten) elimination processes. The modified Michaelis–Menten or target‐mediated elimination was not only concentration–dependent but also time‐dependent. A reduction in target‐mediated clearance over time suggests a reduction in target abundance to a larger extent than associated with concentration alone, which is consistent with the treatment‐induced depletion of the B cells observed in patients who underwent assessment. Linear clearance (CL) and steady‐state volume of distribution were 0.189 L/day and 9.41 L, respectively. Target‐mediated clearance was ~5 L/day at baseline, with an asymptote of ~0.03 L/day at steady state. With the largest covariate effect on odronextamab exposure, baseline body weight was directly correlated with CL and volume of distribution, albumin was inversely correlated with CL and volume of distribution, and baseline interleukin‐10 was inversely correlated with CL.
- Open Access
- 18 November 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (11) , 1731-1734
The Advance of In Silico Evidence to Transform Pediatric Drug Development for Rare Diseases
- 18 November 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (11) , 1731-1734
Open AccessThe Advance of In Silico Evidence to Transform Pediatric Drug Development for Rare Diseases
- Open Access
- 17 March 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (11) , 1823-1834
Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia
Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH). A population pharmacokinetic (PK)/pharmacodynamic (PD) model was previously developed to characterize evinacumab exposure and LDL‐C response in adolescents and adults. In this analysis, the PK/PD model was refined to include children aged 5 to < 12 years and to characterize the lipoprotein apheresis effect on LDL‐C reduction. The PK of evinacumab was characterized by a two‐compartment model with parallel linear and non‐linear elimination. Linear disposition parameters were allometrically scaled by body weight. Baseline ANGPTL3 concentrations and disease status (non‐HoFH vs. HoFH) influenced the maximum target‐mediated rate of elimination but had a minimal effect on evinacumab exposures at 15 mg/kg intravenous doses every 4 weeks across weight/age groups. In patients with HoFH, the LDL‐C reduction was adequately described by an indirect response model in which evinacumab inhibits the formation of LDL‐C and that includes a secondary elimination process quantifying the lipoprotein apheresis effect. Older age was associated with a decrease in baseline LDL‐C. An increase in body weight was associated with a reduction in the maximum inhibitory effect of evinacumab. Model‐based simulations showed that while evinacumab exposure is reduced with decreasing age/body weight, younger patients are predicted to have a comparable or greater magnitude of LDL‐C reduction than older patients at a dose of 15 mg/kg. Overall, the model adequately predicted the evinacumab exposure and LDL‐C reduction in children, adolescents, and adults with HoFH, aligning with clinically relevant observations.
- 17 March 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (11) , 1823-1834
Open AccessPopulation Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia
Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH). A population pharmacokinetic (PK)/pharmacodynamic (PD) model was previously developed to characterize evinacumab exposure and LDL‐C response in adolescents and adults. In this analysis, the PK/PD model was refined to include children aged 5 to < 12 years and to characterize the lipoprotein apheresis effect on LDL‐C reduction. The PK of evinacumab was characterized by a two‐compartment model with parallel linear and non‐linear elimination. Linear disposition parameters were allometrically scaled by body weight. Baseline ANGPTL3 concentrations and disease status (non‐HoFH vs. HoFH) influenced the maximum target‐mediated rate of elimination but had a minimal effect on evinacumab exposures at 15 mg/kg intravenous doses every 4 weeks across weight/age groups. In patients with HoFH, the LDL‐C reduction was adequately described by an indirect response model in which evinacumab inhibits the formation of LDL‐C and that includes a secondary elimination process quantifying the lipoprotein apheresis effect. Older age was associated with a decrease in baseline LDL‐C. An increase in body weight was associated with a reduction in the maximum inhibitory effect of evinacumab. Model‐based simulations showed that while evinacumab exposure is reduced with decreasing age/body weight, younger patients are predicted to have a comparable or greater magnitude of LDL‐C reduction than older patients at a dose of 15 mg/kg. Overall, the model adequately predicted the evinacumab exposure and LDL‐C reduction in children, adolescents, and adults with HoFH, aligning with clinically relevant observations.
- Open Access
- 17 March 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (11) , 1835-1847
Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia
Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH. Population pharmacometric models characterizing evinacumab exposure and LDL‐C response accounting for lipoprotein apheresis effect in ≥ 5‐year‐old patients were adapted for growth and maturation to predict and compare evinacumab and LDL‐C concentrations across age/weight groups in virtual ≥ 6‐month‐old patients receiving 15 mg/kg evinacumab intravenous (iv) infusions every 4 weeks (q4w). As expected from allometric theory, weight‐based dosing resulted in decreasing evinacumab exposures with declining body weight. Consistent with trends observed in > 5‐year‐old patients, the predicted percent change from LDL‐C baseline (%∆LDL‐C) was generally comparable or even higher in < 5‐year‐old patients (63.0%–68.5%) than in 5‐ to < 18‐year‐old patients (61.3%–67.8%) or adults (51.7%), with the predicted percentages of patients achieving %∆LDL‐C > 50% also higher in < 5‐year‐old patients (82.0%–86.9%) versus 5‐ to < 18‐year‐old patients (72.0%–84.5%) and adults (54.8%). Through a managed access program, six 1‐ to < 5‐year‐old patients received between 5 and 23 iv infusions of 15 mg/kg evinacumab q4w. Rapid and clinically meaningful LDL‐C reductions were observed, with %∆LDL‐C at the last reported dose ranging from 41.3% to 77.3%. Based on the actual patient dosing and plasmapheresis history, model‐predicted evinacumab and LDL‐C concentrations were comparable to the observed data collected in the managed access program. Overall, this analysis provides evidence for the use of evinacumab 15 mg/kg iv q4w dosing regimen in 6‐month‐old to 5‐year‐old patients.
- 17 March 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (11) , 1835-1847
Open AccessComparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia
Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH. Population pharmacometric models characterizing evinacumab exposure and LDL‐C response accounting for lipoprotein apheresis effect in ≥ 5‐year‐old patients were adapted for growth and maturation to predict and compare evinacumab and LDL‐C concentrations across age/weight groups in virtual ≥ 6‐month‐old patients receiving 15 mg/kg evinacumab intravenous (iv) infusions every 4 weeks (q4w). As expected from allometric theory, weight‐based dosing resulted in decreasing evinacumab exposures with declining body weight. Consistent with trends observed in > 5‐year‐old patients, the predicted percent change from LDL‐C baseline (%∆LDL‐C) was generally comparable or even higher in < 5‐year‐old patients (63.0%–68.5%) than in 5‐ to < 18‐year‐old patients (61.3%–67.8%) or adults (51.7%), with the predicted percentages of patients achieving %∆LDL‐C > 50% also higher in < 5‐year‐old patients (82.0%–86.9%) versus 5‐ to < 18‐year‐old patients (72.0%–84.5%) and adults (54.8%). Through a managed access program, six 1‐ to < 5‐year‐old patients received between 5 and 23 iv infusions of 15 mg/kg evinacumab q4w. Rapid and clinically meaningful LDL‐C reductions were observed, with %∆LDL‐C at the last reported dose ranging from 41.3% to 77.3%. Based on the actual patient dosing and plasmapheresis history, model‐predicted evinacumab and LDL‐C concentrations were comparable to the observed data collected in the managed access program. Overall, this analysis provides evidence for the use of evinacumab 15 mg/kg iv q4w dosing regimen in 6‐month‐old to 5‐year‐old patients.
- Open Access
- 14 February 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (3) , 375-386
Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a rare genetic disorder caused by decreased or absent dystrophin gene leading to progressive muscle degeneration and weakness in young boys. Disease progression models for the North Star Ambulatory Assessment (NSAA), a functional measurement widely used to assess outcomes in clinical trials, were developed using a longitudinal population modeling approach. The relationship between NSAA total score over time, loss of ambulation, and potential covariates that may influence disease progression were evaluated. Data included individual participant observations from an internal placebo‐controlled phase II clinical trial and from the external natural history database for male patients with DMD obtained through the Cooperative International Neuromuscular Research Group (CINRG). A modified indirect response model for NSAA joined to a loss of ambulation (LOA) time‐to‐event model described the data well. Age was used as the independent variable because ambulatory function is known to vary with age. The NSAA and LOA models were linked using the dissipation rate constant parameter from the NSAA model by including the parameter as a covariate on the hazard equation for LOA. No covariates were identified. The model was then used as a simulation tool to explore various clinical trial design scenarios. This model contributes to the quantitative understanding of disease progression in DMD and may guide model‐informed drug development decisions for ongoing and future DMD clinical trials.
- 14 February 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (3) , 375-386
Open AccessDisease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a rare genetic disorder caused by decreased or absent dystrophin gene leading to progressive muscle degeneration and weakness in young boys. Disease progression models for the North Star Ambulatory Assessment (NSAA), a functional measurement widely used to assess outcomes in clinical trials, were developed using a longitudinal population modeling approach. The relationship between NSAA total score over time, loss of ambulation, and potential covariates that may influence disease progression were evaluated. Data included individual participant observations from an internal placebo‐controlled phase II clinical trial and from the external natural history database for male patients with DMD obtained through the Cooperative International Neuromuscular Research Group (CINRG). A modified indirect response model for NSAA joined to a loss of ambulation (LOA) time‐to‐event model described the data well. Age was used as the independent variable because ambulatory function is known to vary with age. The NSAA and LOA models were linked using the dissipation rate constant parameter from the NSAA model by including the parameter as a covariate on the hazard equation for LOA. No covariates were identified. The model was then used as a simulation tool to explore various clinical trial design scenarios. This model contributes to the quantitative understanding of disease progression in DMD and may guide model‐informed drug development decisions for ongoing and future DMD clinical trials.
- Open Access
- 16 May 2021
- Published by Springer Nature in Drugs in R&D
- Vol. 21 (2) , 217-229
Population Pharmacokinetic Analysis of Rivipansel in Healthy Subjects and Subjects with Sickle Cell Disease
Background Sickle cell disease is an inherited blood disorder with reduced blood-carrying capacity. It is associated with a tendency to form microclots in blood vessels, leading to painful episodes known as a vaso-occlusive crisis. Rivipansel is a pan-selectin inhibitor being studied for the treatment of a vaso-occlusive crisis in patients with sickle cell disease. Methods A population pharmacokinetic model of rivipansel plasma and urine concentrations was constructed using a two-compartment model and data from nine different clinical studies. Creatinine clearance was calculated using the Schwartz formula for children and the Chronic Kidney Disease Epidemiology Collaboration formula for adults. Urine volume and concentration of the study drug in urine from subjects in five clinical studies were used to estimate renal and nonrenal clearance. Results Rivipansel drug concentrations were well described by the model. The post hoc estimates of average steady-state concentrations were predicted to be similar for the adult and pediatric cohorts of the pivotal phase III study. Parameter estimates showed almost exclusively renal excretion of rivipansel, which is consistent with the known properties of the drug. Conclusions The pharmacokinetics of rivipansel was well characterized by a two-compartment population pharmacokinetic model. Our results illustrate the important role of simulations in optimizing a potential drug dosing regimen for patients with sickle cell disease and progressive renal impairment.
- 16 May 2021
- Published by Springer Nature in Drugs in R&D
- Vol. 21 (2) , 217-229
Open AccessPopulation Pharmacokinetic Analysis of Rivipansel in Healthy Subjects and Subjects with Sickle Cell Disease
Background Sickle cell disease is an inherited blood disorder with reduced blood-carrying capacity. It is associated with a tendency to form microclots in blood vessels, leading to painful episodes known as a vaso-occlusive crisis. Rivipansel is a pan-selectin inhibitor being studied for the treatment of a vaso-occlusive crisis in patients with sickle cell disease. Methods A population pharmacokinetic model of rivipansel plasma and urine concentrations was constructed using a two-compartment model and data from nine different clinical studies. Creatinine clearance was calculated using the Schwartz formula for children and the Chronic Kidney Disease Epidemiology Collaboration formula for adults. Urine volume and concentration of the study drug in urine from subjects in five clinical studies were used to estimate renal and nonrenal clearance. Results Rivipansel drug concentrations were well described by the model. The post hoc estimates of average steady-state concentrations were predicted to be similar for the adult and pediatric cohorts of the pivotal phase III study. Parameter estimates showed almost exclusively renal excretion of rivipansel, which is consistent with the known properties of the drug. Conclusions The pharmacokinetics of rivipansel was well characterized by a two-compartment population pharmacokinetic model. Our results illustrate the important role of simulations in optimizing a potential drug dosing regimen for patients with sickle cell disease and progressive renal impairment.
- Open Access
- 26 March 2021
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 21 (5) , 535-543
Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Introduction ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial) demonstrated the efficacy and safety of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM). Model-based analyses from ATTR-ACT can examine predictor effects on dose–response/exposure–response relationships. Methods Parametric hazard distributions were developed for all-cause mortality and frequency of cardiovascular-related hospitalization. Time-to-event models were fitted to survival data, and repeated time-to-event models were fitted to hospitalization data. Disease-specific characteristics were assessed as baseline predictors of event hazards. Results There were 441 patients in this analysis. At month 30, 70.5% (tafamidis) and 57.1% (placebo) of patients were alive, with 154/441 deaths reported; 495 cardiovascular-related hospitalizations occurred. The cumulative risk of death was 42.1% (95% confidence interval [CI] 24.2–58.0) lower with tafamidis than with placebo, regardless of New York Heart Association (NYHA) class; significant predictors of decreased risk were genotype (wild-type), greater 6-Minute Walk Test (6MWT) distance, higher left ventricular ejection fraction (LVEF), and lower blood urea nitrogen (BUN) and N-terminal pro-B-type natriuretic peptide concentrations. The average cumulative risk of cardiovascular-related hospitalization up to 30 months was 40.8% (95% CI 31.0–49.7) lower with tafamidis in NYHA class I/II patients. Significant predictors of reduced risk were greater 6MWT distance, higher LVEF, and lower BUN and troponin I concentrations. Conclusions Tafamidis reduced cumulative mortality and hospitalization risk versus placebo in patients with ATTR-CM. Baseline predictors of outcome were consistent with the cardiovascular nature of the disease and suggested that earlier treatment may improve outcomes. Clinical Trials.gov Identifier NCT01994889 (date of registration: November 26, 2013).
- 26 March 2021
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 21 (5) , 535-543
Open AccessModeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Introduction ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial) demonstrated the efficacy and safety of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM). Model-based analyses from ATTR-ACT can examine predictor effects on dose–response/exposure–response relationships. Methods Parametric hazard distributions were developed for all-cause mortality and frequency of cardiovascular-related hospitalization. Time-to-event models were fitted to survival data, and repeated time-to-event models were fitted to hospitalization data. Disease-specific characteristics were assessed as baseline predictors of event hazards. Results There were 441 patients in this analysis. At month 30, 70.5% (tafamidis) and 57.1% (placebo) of patients were alive, with 154/441 deaths reported; 495 cardiovascular-related hospitalizations occurred. The cumulative risk of death was 42.1% (95% confidence interval [CI] 24.2–58.0) lower with tafamidis than with placebo, regardless of New York Heart Association (NYHA) class; significant predictors of decreased risk were genotype (wild-type), greater 6-Minute Walk Test (6MWT) distance, higher left ventricular ejection fraction (LVEF), and lower blood urea nitrogen (BUN) and N-terminal pro-B-type natriuretic peptide concentrations. The average cumulative risk of cardiovascular-related hospitalization up to 30 months was 40.8% (95% CI 31.0–49.7) lower with tafamidis in NYHA class I/II patients. Significant predictors of reduced risk were greater 6MWT distance, higher LVEF, and lower BUN and troponin I concentrations. Conclusions Tafamidis reduced cumulative mortality and hospitalization risk versus placebo in patients with ATTR-CM. Baseline predictors of outcome were consistent with the cardiovascular nature of the disease and suggested that earlier treatment may improve outcomes. Clinical Trials.gov Identifier NCT01994889 (date of registration: November 26, 2013).
- Open Access
- 14 February 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (9) , 3574-3587
Population pharmacokinetic modelling and simulation of tafamidis in healthy subjects and patients with transthyretin amyloidosis
Aims: Since the first approval for transthyretin amyloid polyneuropathy patients, new formulations and different strength of tafamidis have been developed and tested in a different population (transthyretin amyloid cardiomyopathy). The objective of this analysis was to develop a unified population pharmacokinetic (PK) model of tafamidis, which can describe the PK of various different formulations in healthy subjects as well as patients with TTR amyloidosis, and to understand effects of intrinsic and extrinsic factors on the PK variability.Methods: Pooled data from 23 clinical studies (17 Phase 1 and 6 Phase 2/3 studies) were used for the analysis. The plasma concentration–time data were analysed using a nonlinear mixed effects modelling methodology. Covariate analysis was performed using a stepwise covariate model building procedure.Results: The final model was a 2‐compartment model with first‐order absorption and elimination coupled with an absorption lag time for nonsolution formations. Body weight, food and tafamidis formulations were incorporated as structural covariates on PK parameters. Covariate analysis further identified age ≥65 years (14.5% decrease) and moderate hepatic impairment effects (57.6% increase) on apparent clearance and transthyretin amyloid polyneuropathy effect (17.3% decrease) on F. However, model‐based clinical trial simulation results indicated that tafamidis steady‐state exposure changes were not clinically meaningful under the tested conditions.Conclusions: The unified population PK model of tafamidis was developed based on 23 studies. Subsequent clinical trial simulations indicated that no significant changes in tafamidis exposure necessitating a dose modification are expected due to either extrinsic or intrinsic factors. The model was used to support labelling statements for dose recommendations in special populations.
- 14 February 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (9) , 3574-3587
Open AccessPopulation pharmacokinetic modelling and simulation of tafamidis in healthy subjects and patients with transthyretin amyloidosis
Aims: Since the first approval for transthyretin amyloid polyneuropathy patients, new formulations and different strength of tafamidis have been developed and tested in a different population (transthyretin amyloid cardiomyopathy). The objective of this analysis was to develop a unified population pharmacokinetic (PK) model of tafamidis, which can describe the PK of various different formulations in healthy subjects as well as patients with TTR amyloidosis, and to understand effects of intrinsic and extrinsic factors on the PK variability.Methods: Pooled data from 23 clinical studies (17 Phase 1 and 6 Phase 2/3 studies) were used for the analysis. The plasma concentration–time data were analysed using a nonlinear mixed effects modelling methodology. Covariate analysis was performed using a stepwise covariate model building procedure.Results: The final model was a 2‐compartment model with first‐order absorption and elimination coupled with an absorption lag time for nonsolution formations. Body weight, food and tafamidis formulations were incorporated as structural covariates on PK parameters. Covariate analysis further identified age ≥65 years (14.5% decrease) and moderate hepatic impairment effects (57.6% increase) on apparent clearance and transthyretin amyloid polyneuropathy effect (17.3% decrease) on F. However, model‐based clinical trial simulation results indicated that tafamidis steady‐state exposure changes were not clinically meaningful under the tested conditions.Conclusions: The unified population PK model of tafamidis was developed based on 23 studies. Subsequent clinical trial simulations indicated that no significant changes in tafamidis exposure necessitating a dose modification are expected due to either extrinsic or intrinsic factors. The model was used to support labelling statements for dose recommendations in special populations.